COVID-19 vaccines that specifically target the Omicron and other variants are under development, Pfizer Inc.’s chief executive said on Wednesday, adding that the company will be able to quickly adapt shots as the novel coronavirus mutates.
The United States has begun distributing COVID vaccines for children as young as six months around the country, and availability of the shots will improve in the coming days, according to White House COVID-19 response coordinator Dr. Ashish Jha.
The rollout in the United States this week of COVID vaccines for children as young as six months is likely to start slowly, and then pick up in the coming days, according to White House COVID-19 response coordinator Ashish Jha.
Bavarian Nordic announced Thursday that the upcoming Phase III trial for ABNCoV2, the Denmark-based biotech company’s COVID-19 booster candidate, has been redesigned to compete against Pfizer-BioNTech’s mRNA-based vaccine.
On Friday, the World Trade Organization approved vaccine patent waivers to increase the availability of COVID-19 vaccines to lower-income countries.
The U.S. Food and Drug Administration on Friday authorized two COVID-19 vaccines for children aged 5 and under, opening the door to vaccinating millions of the country’s youngest children.
The European Medicines Agency (EMA) started a rolling review on Friday of a variant-adapted COVID-19 vaccine from Moderna, as coronavirus cases linked to Omicron sub-variants see an uptick in the region.
Advisers to the U.S Food and Drug Administration on Wednesday unanimously recommended the agency authorize COVID-19 vaccines from Moderna Inc. and Pfizer Inc./BioNTech SE for millions of the youngest American children.
Advisers to the U.S. Food and Drug Administration on Tuesday unanimously recommended that the agency authorize Moderna Inc’s (MRNA.O) COVID-19 vaccine for children and teens aged 6 to 17 years of age.
Moderna’s (MRNA.O) COVID-19 vaccine may have a higher risk of heart inflammation in young men than the Pfizer (PFE.N)/BioNTech (22UAy.DE) shot, according to data presented on Tuesday to U.S. Food and Drug Administration advisers weighing its use for those aged 6 to 17.